Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
ATLCAR.CD138 are autologous T-lymphocytes that are engineered to express a chimeric antigen receptor that targets CD138, potentially resulting in an immune response against CD138-expressing tumor cells and leading to an antitumor response (PMID: 31040928).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|ATLCAR.CD138 + Cyclophosphamide + Fludarabine||ATLCAR.CD138 Cyclophosphamide Fludarabine||0||1|